Phospho-PPP1R2 (S44) Antibody

What is PPP1R2 and why is the phosphorylation at Ser44 significant?

PPP1R2 (Protein Phosphatase 1 Regulatory Inhibitor Subunit 2), also known as Inhibitor-2 (IPP-2), is one of the first regulatory subunits identified as an inhibitor and binding partner of Ser/Thr phosphoprotein phosphatase 1 (PPP1). It forms a stable complex with the PPP1 catalytic subunit (PPP1C), blocking the active site and potently inhibiting it . The phosphorylation at Ser44 is particularly significant as it's involved in the regulation of the inhibitory function of PPP1R2. Recent research indicates that phosphorylation at different sites of PPP1R2 can modulate its interaction with PPP1C, affecting various cellular processes including mitosis, meiosis, cardiac function, and neuronal cell survival .

What are the primary applications for Phospho-PPP1R2 (S44) Antibody?

The Phospho-PPP1R2 (S44) Antibody is designed for detecting endogenous levels of IPP-2 protein specifically when phosphorylated at Ser44 . The primary research applications include:

• Western Blotting (WB): For quantitative detection of phosphorylated PPP1R2 in protein samples (recommended dilution 1:500-1:2000)

• Immunohistochemistry (IHC): For detection in tissue sections (recommended dilution 1:100-1:300)

• ELISA: For highly sensitive quantification (recommended dilution 1:40000)

These applications enable researchers to investigate the phosphorylation state of PPP1R2 in various experimental contexts, particularly in studying signaling pathways involving protein phosphatase 1 regulation.

How should I optimize Western blot protocols for detecting phosphorylated PPP1R2?

Successful detection of phosphorylated PPP1R2 requires optimization of several parameters:

• Sample Preparation:

  • Use phosphatase inhibitors in lysis buffers to prevent dephosphorylation

  • Process samples quickly and keep them cold throughout

  • Consider using phosphatase treatments as negative controls

• Blocking and Antibody Incubation:

  • Use BSA instead of milk for blocking (5% BSA in TBST is recommended)

  • Dilute Phospho-PPP1R2 (S44) Antibody 1:500-1:2000 in blocking buffer

  • Consider overnight incubation at 4°C for improved signal-to-noise ratio

• Detection and Quantification:

  • For multiplexed detection, use fluorescent secondary antibodies to simultaneously detect total and phosphorylated forms

  • Include loading controls like tubulin for normalization

  • Quantify phosphorylation levels by comparing band intensities between treated and untreated samples

For validation purposes, include appropriate controls such as PPP1R2 knockout cell lines and lambda phosphatase treatment to confirm the specificity of the phospho-signal.

What are the appropriate positive controls when using this antibody?

When using Phospho-PPP1R2 (S44) Antibody, appropriate positive controls include:

• Cell Lines with Known PPP1R2 Expression:

  • HeLa cells have been validated for PPP1R2 expression and are suitable positive controls

  • COLO cells, HepG2 cells, and HUVEC cells have also been used successfully in Western blot validation

• Treated Samples:

  • Samples treated with agents that enhance Ser44 phosphorylation (such as specific kinase activators)

  • Phosphorylation at Ser44 has been linked to ATM kinase activity , so DNA damage-inducing agents that activate ATM may increase this phosphorylation

• Recombinant Proteins:

  • Synthetic phosphopeptides containing the phosphorylated Ser44 site can serve as positive controls for antibody specificity

Include paired negative controls such as samples treated with lambda phosphatase to remove phosphorylation and validate antibody specificity.

How can I use Phospho-PPP1R2 (S44) Antibody to investigate the dual role of PPP1R2 as both an inhibitor and stabilizer of PP1 complexes?

Recent research has revealed that PPP1R2 functions not just as an inhibitor but also as a stabilizer of specific PP1 holoenzymes . To investigate this dual role:

• Co-immunoprecipitation Studies:

  • Use Phospho-PPP1R2 (S44) Antibody to immunoprecipitate phosphorylated PPP1R2

  • Analyze co-precipitated proteins by mass spectrometry to identify differential binding partners of phosphorylated vs. non-phosphorylated PPP1R2

  • Focus particularly on PP1:RepoMan complexes, which have been shown to be stabilized by PPP1R2

• Proximity Ligation Assays:

  • Employ proximity ligation assays using Phospho-PPP1R2 (S44) Antibody paired with antibodies against PP1 catalytic subunits or other regulatory subunits like RepoMan

  • This approach can visualize and quantify interactions in situ

• Functional Assays:

  • Compare phosphatase activity in the presence of wild-type PPP1R2 versus phospho-deficient (S44A) mutants

  • Assess the impact of kinases that phosphorylate Ser44 (such as ATM) on PP1 complex stability and activity

These approaches will help elucidate how phosphorylation at Ser44 affects the switch between inhibitory and stabilizing functions of PPP1R2 in different cellular contexts.

What methodological approaches can be used to distinguish between PPP1R2 and its pseudogenes when using phospho-specific antibodies?

PPP1R2 has several pseudogenes (at least ten have been found throughout the human genome) , which complicates specific detection. To distinguish between PPP1R2 and its pseudogenes:

• Sequence Analysis and Epitope Mapping:

  • Compare the sequences around Ser44 in PPP1R2 and its pseudogenes

  • Confirm whether the epitope recognized by the antibody is conserved in pseudogenes

• Validation in Knockout Models:

  • Use PPP1R2 knockout cell lines as negative controls

  • If the antibody still detects signals in knockout lines, this may indicate cross-reactivity with pseudogenes

• RNA Interference Combined with Protein Detection:

  • Conduct siRNA knockdown specifically targeting PPP1R2 but not its pseudogenes

  • Assess changes in phospho-signal using the antibody

  • Persistent signals despite confirmed mRNA knockdown may indicate pseudogene protein expression

• Mass Spectrometry Validation:

  • Use immunoprecipitation with the phospho-antibody followed by mass spectrometry

  • Identify unique peptides that differentiate between PPP1R2 and its pseudogenes

This multi-faceted approach ensures accurate attribution of signals to PPP1R2 rather than its pseudogenes, which is essential for meaningful data interpretation.

How can I verify the specificity of Phospho-PPP1R2 (S44) Antibody in my experimental system?

Verifying antibody specificity is crucial for reliable results. For Phospho-PPP1R2 (S44) Antibody, implement these validation steps:

• Phosphatase Treatment Controls:

  • Divide your samples and treat half with lambda phosphatase

  • Run treated and untreated samples side by side on Western blot

  • A specific phospho-antibody signal should disappear in phosphatase-treated samples

• Peptide Competition Assay:

  • Pre-incubate the antibody with excess phosphorylated and non-phosphorylated peptides containing the Ser44 site

  • A specific antibody signal should be blocked by the phosphorylated peptide but not by the non-phosphorylated variant

• Genetic Models:

  • Use PPP1R2 knockout cell lines as negative controls

  • Compare with site-specific phospho-mutants (S44A) that cannot be phosphorylated at this position

• Stimulus-Response Validation:

  • Treat cells with stimuli known to affect Ser44 phosphorylation

  • Verify that the antibody signal changes appropriately with treatment

What are the most common sources of false positives/negatives when using phospho-specific antibodies like Phospho-PPP1R2 (S44), and how can these be mitigated?

Phospho-specific antibodies are prone to several sources of error that require careful consideration:

Sources of False Positives:

• Cross-reactivity with similar phospho-epitopes:

  • Mitigation: Perform epitope mapping and validate with phospho-deficient mutants

  • Use peptide competition assays with related phospho-peptides to assess cross-reactivity

• Detection of pseudogene products:

  • Mitigation: Validate in knockout models and compare with gene-specific knockdowns

  • Use orthogonal techniques like mass spectrometry for confirmation

• Incomplete blocking:

  • Mitigation: Use BSA instead of milk (milk contains phosphoproteins)

  • Optimize blocking time and temperature

Sources of False Negatives:

• Sample dephosphorylation during preparation:

  • Mitigation: Use comprehensive phosphatase inhibitor cocktails

  • Maintain cold temperatures throughout sample handling

  • Consider acidic extraction methods to denature phosphatases

• Epitope masking by protein interactions:

  • Mitigation: Test different extraction and denaturation conditions

  • Consider native vs. denaturing immunoprecipitation approaches

• Low sensitivity:

  • Mitigation: Use signal amplification methods

  • Optimize antibody concentration and incubation time

  • Consider enhanced chemiluminescence systems for Western blot detection

Implementing these mitigation strategies will significantly improve the reliability of results when working with Phospho-PPP1R2 (S44) Antibody.

How can Phospho-PPP1R2 (S44) Antibody be utilized to investigate the role of PPP1R2 in neurodevelopmental processes?

The PPP1C/PPP1R2 complex has been implicated in neuronal cell survival , making it a potentially important factor in neurodevelopment. To investigate this role:

• Developmental Expression Analysis:

  • Use the antibody to track phosphorylation changes during neural development in primary cultures or brain tissue sections

  • Compare phosphorylation patterns across different brain regions and developmental stages

• Activity-Dependent Phosphorylation:

  • Examine how neuronal activity affects Ser44 phosphorylation status

  • Correlate phosphorylation changes with functional outcomes like neurite outgrowth or synapse formation

• Integration with Neurodevelopmental Disorder Models:

  • Apply the antibody in models of neurodevelopmental disorders where phosphatase activity may be dysregulated

  • Compare with related phosphatase regulatory subunits like PPP2R5D, which has established links to neurodevelopmental delay and intellectual disability

These approaches can reveal whether specific phosphorylation events on PPP1R2 serve as molecular switches in neurodevelopmental processes and if they might represent therapeutic targets in neurodevelopmental disorders.

What methodological considerations are important when designing experiments to investigate the interplay between different phosphorylation sites on PPP1R2?

PPP1R2 contains multiple phosphorylation sites including Ser44, Ser120/Ser121, and others, with potentially complex interrelationships. When investigating these interactions:

• Temporal Phosphorylation Mapping:

  • Use Phospho-PPP1R2 (S44) Antibody alongside antibodies for other sites (such as Ser120/Ser121)

  • Perform time-course experiments to determine the sequence of phosphorylation events

  • Consider pulse-chase approaches with phosphatase inhibitors to track site-specific persistence

• Multiplexed Detection Approaches:

  • Implement fluorescent multiplexing in Western blots to simultaneously detect multiple phosphorylation sites

  • Set up experimental designs as follows:

• Mutational Analysis:

  • Generate phospho-mimetic and phospho-deficient mutants in combinations (e.g., S44A/S120D)

  • Assess functional outcomes of these combinations on PP1 activity and binding

• Mass Spectrometry Approaches:

  • Use immunoprecipitation with site-specific antibodies followed by mass spectrometry

  • Identify co-occurring phosphorylation patterns to determine whether sites are hierarchical or independent